Skip to main content

Table 3 Factors influencing KRAS testing in metastatic CRC patients

From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

  KRAS testing
n = 190/290 (65.5%)
Univariate analysis
P-Value
Multivariate analysis
Odds ratio 95% CI P-Value
Age (years)   < 0.0001    < 0.0001
  > 75 42 / 107 (39.3%)   1 Ref  
 60–75 97 / 126 (77.0%)   4.72 2.54–8.77  
  < 60 51 / 57 (89.5%)   10.78 4.07–28.50  
Sex   0.016    0.33
 Women 82 / 140 (58.6%)   1 Ref  
 Men 108 / 150 (72.0%)   1.34 0.75–2.41  
Site of the primary tumour   0.0011    0.006
 Rectum 35 / 64 (54.7%)   1 Ref  
 Right colon 51 / 90 (56.7%)   1.44 0.67–3.07  
 Left colon 104 / 136 (76.5%)   3.09 1.48–6.45  
Tumour grade (MD = 40)   0.52    
 Well 63 / 89 (70.8%)     
 Moderate 83 / 131 (63.4%)     
 Poor 20 / 30 (66.7%)     
Geographical area of primary treatment (MD = 2)   0.0001    0.010
 Charente-Maritime 42 / 87 (48.3%)   1 Ref  
 Charente 32 / 53 (60.4%)   1.99 0.89–4.46  
 Deux-Sèvres 37 / 45 (82.2%)   4.64 1.77–12.18  
 Vienne 61 / 79 (77.2%)   2.88 1.36–6.13  
 Outside the region 17 / 24 (70.8%)   2.02 0.67–6.12  
Status of the center (MD = 2)   0.026a    
 Public Hospital 60 / 83 (72.3%)  
 Private hospital 83 / 143 (58.0%)     
 University hospital 46 / 62 (74.2%)     
  1. 95% CI 95% confidence interval, MD missing data, Ref reference
  2. aNot retained in the final multivariate model